Mereo BioPharma Group Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 23, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	57	524	293	82	153	198
Market Cap Growth	-88.00%	78.98%	257.14%	-46.41%	-22.61%	244.96%
Enterprise Value	16	452	255	15	44	180
Last Close Price	0.35	3.48	2.04	0.54	1.36	2.82
PE Ratio	-	-	-	-	10.09	-
PS Ratio	134.36	-	32.34	-	3.52	-
PB Ratio	1.44	8.89	6.40	1.70	1.46	-11.82
P/TBV Ratio	1.46	8.99	6.54	1.70	2.02	-
EV/Sales Ratio	38.31	-	28.17	-	1.02	-
Debt / Equity Ratio	0.01	0.11	0.12	0.30	0.19	-1.20
Net Debt / Equity Ratio	-1.04	-1.04	-1.02	-1.03	-0.88	0.37
Net Debt / EBITDA Ratio	1.07	1.40	1.94	1.01	3.72	0.15
Net Debt / FCF Ratio	1.48	1.93	2.44	1.08	13.43	0.20
Asset Turnover	0.01	-	0.14	-	0.39	-
Quick Ratio	8.35	5.24	6.38	2.89	7.66	3.23
Current Ratio	8.71	5.40	6.72	3.09	7.92	3.47
Return on Equity (ROE)	-69.79%	-77.58%	-57.81%	-53.63%	34.85%	-1294.27%
Return on Assets (ROA)	-39.81%	-39.99%	-23.57%	-28.67%	-13.82%	-31.43%
Return on Invested Capital (ROIC)	-	-	-	-825.95%	-	-220.12%
Return on Capital Employed (ROCE)	-95.30%	-73.10%	-47.60%	-99.40%	-18.40%	-69.10%
Earnings Yield	-61.88%	-7.98%	-9.11%	-48.22%	9.91%	-92.45%
FCF Yield	-48.72%	-6.06%	-6.54%	-55.78%	-4.50%	-16.02%
Buyback Yield / Dilution	-9.71%	-12.16%	-9.33%	-8.63%	-63.82%	-279.04%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.